PTGS2 rs1799985: Understanding the -765 G/C Promoter Variant
The rs1799985 variant, often referred to as the -765 G/C promoter polymorphism, is a genetic change located in the PTGS2 gene. This gene encodes the COX-2 enzyme, which plays a critical role in inflammation, and the variant is studied for its potential influence on gene expression and health outcomes.
What each genotype means
Common promoter genotype
This is the most common genotype for this variant. Research into whether this specific promoter sequence influences COX-2 expression or disease risk has yielded mixed and often contradictory results across different populations. Please discuss any concerns regarding medication response or health risks with your clinician.
This is the major allele genotype, carried by the majority of individuals in most global populations.
Heterozygous promoter variant
You carry one copy of the C allele, which has been studied for its potential role in altering PTGS2 transcriptional activity. While some studies have explored associations with cancer or inflammatory conditions, the evidence remains limited and inconsistent. Consult your healthcare provider if you have questions about how this might relate to your personal health history.
Carried by a significant portion of the population, with a minor allele frequency of approximately 0.15 in European populations.
Variant promoter genotype
You carry two copies of the C allele, a variant that has been investigated for its potential to influence COX-2 expression. Some research has suggested associations with altered disease risk, such as rectal cancer, but these findings have not been consistently replicated across all studies. Because the clinical significance of this variant is not well-established, please discuss any health concerns or medication responses with your doctor or pharmacist.
This is the less common genotype, occurring in a smaller percentage of the population compared to the G allele.
What is the rs1799985 Variant?
The rs1799985 variant is a single nucleotide polymorphism (SNP) situated in the promoter region of the PTGS2 gene. In genetics, a promoter region acts as an 'on-off' switch that controls how much of a specific protein is produced by a cell. This particular variant involves a substitution where a guanine (G) base is replaced by a cytosine (C) base. Because it sits in a regulatory area, researchers have long hypothesized that this change might alter the binding of transcription factors, potentially leading to differences in how much COX-2 enzyme is synthesized in response to inflammatory stimuli. While it is a well-documented site in genetic research, it is important to note that the functional impact of this change can vary depending on the tissue type and the specific biological context being studied.
The Role of the PTGS2 Gene
The PTGS2 gene provides instructions for making the enzyme cyclooxygenase-2, commonly known as COX-2. This enzyme is a key player in the body's inflammatory response, as it is responsible for converting arachidonic acid into prostaglandins—signaling molecules that promote inflammation, pain, and fever. Unlike its counterpart, COX-1, which is constitutively expressed to maintain normal physiological functions like protecting the stomach lining, COX-2 is typically 'inducible.' This means its levels rise significantly when the body experiences injury or inflammation. Because of its central role in these pathways, PTGS2 is the primary target for non-steroidal anti-inflammatory drugs (NSAIDs), such as celecoxib. Understanding how genetic variations in the promoter region might influence the expression of this enzyme is a major area of interest for scientists studying chronic inflammatory conditions and drug responses.
Research Associations and Evidence Strength
Research into rs1799985 has yielded mixed and sometimes conflicting results, leading to a classification of limited evidence regarding its clinical utility. Some studies have suggested that the C allele might be associated with a lower risk of end-stage osteoarthritis, while other investigations have explored its potential link to cardiovascular markers, such as HDL-cholesterol levels or the risk of Type 2 diabetes. However, other studies have failed to find significant differences in how the body responds to common NSAIDs like celecoxib based on this genotype. Because these findings are often based on specific populations or small sample sizes, the scientific community has not reached a consensus on the variant's overall impact. It is essential to view these associations as statistical observations rather than definitive predictors of individual health outcomes or medication efficacy.
What You Can and Cannot Do With This Information
Genetic information regarding rs1799985 is primarily for educational purposes and should not be used to make personal medical decisions. While it is natural to be curious about how your genetics might influence your health, this variant does not provide a clear-cut diagnosis or a reliable guide for medication dosing. If you are concerned about your risk for inflammatory conditions or have questions about how you respond to anti-inflammatory medications, the most important step is to consult with your healthcare provider or a pharmacist. They can evaluate your full medical history, current symptoms, and other relevant factors to provide personalized guidance. Never change your medication regimen or ignore medical advice based on genetic test results, as these findings are only one small piece of a much larger and more complex biological puzzle.
How common is this variant?
The minor allele frequency (MAF) for the C allele of rs1799985 is approximately 0.15 in European populations, though frequencies can vary across different global ancestries.
Frequently asked questions
Is rs1799985 the same as rs20417?
Yes, rs1799985 and rs20417 are different identifiers for the same single nucleotide polymorphism in the PTGS2 promoter region. Researchers often use these terms interchangeably in scientific literature.
Does this variant mean I will have a bad reaction to NSAIDs?
Current research does not support using this variant to predict adverse reactions to NSAIDs. Studies on how this variant affects drug response have been inconsistent, and you should always discuss medication concerns with your doctor.
Can I use this SNP to predict my risk of arthritis?
While some studies have observed statistical associations between this variant and osteoarthritis risk, it is not a diagnostic tool. Many factors, including lifestyle, age, and other genetic markers, contribute to the development of arthritis.
Should I get tested for this variant?
There is currently no clinical recommendation to test for this variant. Because the evidence regarding its impact is limited and mixed, it does not provide actionable information for standard medical care.
Sources & further reading
Educational information only, last refreshed 10/16/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1799985?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29